Core Insights - Longeveron Inc. supports the passing of the Mikaela Naylon Give Kids a Chance Act, which reauthorizes the Rare Pediatric Disease Priority Review Voucher Program, incentivizing the development of treatments for rare pediatric diseases [2][3]. Company Overview - Longeveron Inc. is a clinical stage biotechnology company focused on developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions [2][9]. - The company's lead investigational product is laromestrocel (Lomecel-B™), an allogeneic mesenchymal stem cell therapy aimed at addressing unmet medical needs in various disease areas, including Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease, and Pediatric Dilated Cardiomyopathy [9]. Legislative Impact - The Mikaela Naylon Give Kids a Chance Act allows companies to receive a priority review voucher upon FDA approval of a therapy for rare pediatric diseases, which can be used for expedited review of future therapies or sold [3][8]. - Since August 2024, these vouchers have been sold for $150-200 million each, with over 60 vouchers awarded for 40 pediatric diseases since the program's inception [3]. Clinical Development - Longeveron is currently conducting the ELPIS II Phase 2b clinical trial for laromestrocel in children with HLHS, enrolling 40 pediatric patients across twelve leading treatment institutions [5]. - Top-line results from the ELPIS II trial are expected in the third quarter of 2026, and if positive, the company plans to submit a Biological License Application (BLA) for full approval [5]. Unmet Medical Need - HLHS is a severe congenital heart defect with a high mortality rate, where only 50% of affected infants survive to adolescence despite current treatment options [4][6]. - There is a significant unmet medical need to improve right ventricular function in HLHS patients to enhance both short-term and long-term outcomes [6].

Core Viewpoint - Atossa Therapeutics has reaffirmed its strong market position in the Duchenne Muscular Dystrophy (DMD) program following the reauthorization of the Rare Pediatric Disease Priority Review Voucher (PRV) Program, which allows for potential future PRV eligibility upon FDA approval of (Z)-endoxifen for DMD treatment [1][3] Group 1: Rare Pediatric Disease Designation - The Rare Pediatric Disease (RPD) designation is granted to drug candidates for serious or life-threatening diseases affecting individuals from birth to 18 years old, allowing for eligibility for a PRV upon FDA approval [2][4] - PRVs can be used for priority review of future applications or sold to other sponsors, with recent PRV sales ranging from $150 million to $200 million [2] Group 2: Company Statements and Insights - The renewal of the PRV program signals congressional recognition of the complexities and financial burdens in drug development, validating the potential of (Z)-endoxifen for DMD treatment [3] - Atossa's leadership emphasizes the urgent need for better treatment options for DMD beyond current therapies, highlighting (Z)-endoxifen's broader treatment approach [3] Group 3: Product and Market Potential - (Z)-endoxifen is a Selective Estrogen Receptor Modulator/Degrader (SERM/D) with a favorable safety profile and distinct pharmacology, currently not approved for any indication [6] - The company is advancing (Z)-endoxifen's development in both oncology and rare diseases, supported by a growing global intellectual property portfolio [7][8]